Full Library
Therapy with Allogeneic SARS-CoV-2-specific T-cells for Persistent COVID-19 in Immunocompromised Patients
Resource type
Journal Article
Authors/contributors
- Haidar, Ghady (Author)
- Jacobs, Jana L (Author)
- Hughes Kramer, Kailey (Author)
- Naqvi, Asma (Author)
- Heaps, Amy (Author)
- Parikh, Urvi (Author)
- McCormick, Kevin D (Author)
- Sobolewski, Michele D (Author)
- Agha, Mounzer (Author)
- Bogdanovich, Tatiana (Author)
- Bushunow, Vasilii (Author)
- Farah, Rafic (Author)
- Hensley, Matthew (Author)
- Hsu, Yen-Michael S (Author)
- Johnson, Bruce (Author)
- Klamar-Blain, Cynthia (Author)
- Kozar, Jennifer (Author)
- Lendermon, Elizabeth (Author)
- Macatangay, Bernard JC (Author)
- Marino, Christopher C (Author)
- Raptis, Anastasios (Author)
- Salese, Erin (Author)
- Silveira, Fernanda P (Author)
- Leen, Ann M (Author)
- Marshall, William L (Author)
- Miller, Michael (Author)
- Patel, Badrish (Author)
- Atillasoy, Ercem (Author)
- Mellors, John W (Author)
Title
Therapy with Allogeneic SARS-CoV-2-specific T-cells for Persistent COVID-19 in Immunocompromised Patients
Abstract
We administered SARS-CoV-2 VST under emergency IND to 6 immunocompromised patients with persistent COVID-19 and characterized clinical and virologic responses: three patients had partial responses after failing other therapies but then died. Two patients completely recovered, but the role of VST in recovery was unclear due to concomitant use of other antivirals. One patient had not responded to two courses of remdesivir and experienced sustained recovery after VST. The use VST in immunocompromised patient with persistent COVID-19 requires further study.
Publication
Clinical Infectious Diseases
Date
2023-04-20
Pages
ciad233
Journal Abbr
Clinical Infectious Diseases
Accessed
4/29/23, 8:50 AM
ISSN
1058-4838
Library Catalog
Silverchair
Citation
Haidar, G., Jacobs, J. L., Hughes Kramer, K., Naqvi, A., Heaps, A., Parikh, U., McCormick, K. D., Sobolewski, M. D., Agha, M., Bogdanovich, T., Bushunow, V., Farah, R., Hensley, M., Hsu, Y.-M. S., Johnson, B., Klamar-Blain, C., Kozar, J., Lendermon, E., Macatangay, B. J., … Mellors, J. W. (2023). Therapy with Allogeneic SARS-CoV-2-specific T-cells for Persistent COVID-19 in Immunocompromised Patients. Clinical Infectious Diseases, ciad233. https://doi.org/10.1093/cid/ciad233
DRUGS AND THERAPIES
Link to this record